The Vacc-C5 clinical trial is included as part of the doctor thesis of Kristin Brekke at Oslo University Hospital Background Levels of non-neutralising antibodies (AB) to the C5 domain of HIV Env gp120 are inversely related to progression of HIV infection. In this phase I/II clinical study we investigated safety of Vacc-C5, a peptide-based therapeutic …
The Research Council of Norway’s 10th Conference on Global Health and Vaccination Research where Bionor presents the Vacc-4x REDUC clinical trial results. The REDUC clinical trial was partly funded by a GLOBVAC grant. http://www.forskningsradet.no/prognett-globvac/GLOBVAC_Conference_2017/1253954270899
CSO Maja Sommerfelt was invited as an honorable speaker at Vaccines 2017 in Baltimore, USA, where she presented data from the REDUC clinical trial and chaired the session “HIV/AIDS Vaccines & Clinical Trials, Human Vaccines – Infectious & Non Infectious Diseases & Immunology/Animal models”
